AB Sciex, Alturas Partner on Workflows for Dried Blood Spot Analysis | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – AB Sciex and Alturas Analytics today announced a deal combining technologies from both firms to drive adoption of dried blood spot analysis for drug discovery and development.

Under the terms of the deal, Alturas scientists will use AB Sciex's QTrap 5500 mass spectrometry platform and novel microflow chromatography technology from AB Sciex's Eksigent business to build out workflows for dried blood spot analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.